Analyst consensus rating
Fate Therapeutics Analyst Rating: Buy
Direct answer
Fate Therapeutics's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $5.74.
Forecast evidence checked October 19, 2026.
Get free Fate Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.79
- Average price target
- $5.74
- High price target
- $8.00
- Low price target
- $2.20
- Low target gap
- +22.9%
- Target upside
- +220.9%
- High target gap
- +346.9%
- Target range width
- 324%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Fate Therapeutics?
Fate Therapeutics has a verified Buy consensus. The same dataset has an average price target of $5.74.
How far are Fate Therapeutics's low and high targets from the recorded price?
The low target implies +22.9%, while the high target implies +346.9%.
How many analysts are included in Fate Therapeutics's consensus?
The verified consensus includes 9 analysts.
How is Fate Therapeutics's target upside or downside calculated?
The average target of $5.74 is divided by the recorded price of $1.79, then one is subtracted to produce +220.9%. This does not guarantee a future return.
When was Fate Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.